

ASX ANNOUNCEMENT | 07 JULY 2026

Imagion Biosystems Extends Collaboration with Siemens Healthineers for Phase 2 Clinical Trial

Key Highlights:

- The existing Collaboration Agreement with Siemens Healthineers has been extended in support of the MagSense® Phase 1b/2 HER2 Breast Cancer clinical trial
- Siemens Healthineers, a global leader in MRI technology, will provide in-kind contributions of expertise and technical support
- Collaboration will facilitate the integration of advanced quantitative imaging techniques in trial protocol and clinical site training

Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier and more accurate detection of cancers, is pleased to announce it has renewed and extended its Collaboration Agreement with Siemens Healthineers. The renewal of the agreement provides for critical support and Magnetic Resonance Imaging (MRI) expertise as the company prepares to initiate its recently cleared Phase 1b/2 clinical trial for the MagSense® HER2 Breast Cancer Imaging Agent.

Through the renewed collaboration, Siemens Healthineers will continue to make in-kind contributions of expertise and limited technical support to clinical sites, working with Imagion and its clinical advisors and investigators to optimize the MRI protocols being used in the trial. Importantly, this collaboration will help facilitate successful implementation of the advanced quantitative imaging techniques developed during the company's research collaboration with Wayne State University. The quantitative imaging techniques that will be deployed in the trial are expected to provide improved image quality even with lower doses of the MagSense® imaging agent and reduce imaging time for improved clinical workflow. Additionally, the company anticipates that these imaging techniques combined with the imaging agent could enable the future development of AI diagnostic and image interpretation tools.

"We are very appreciative of the collaboration with Siemens Healthineers and grateful for their continued interest in the MagSense® technology," said Ward Detwiler, President of Imagion's U.S. operating subsidiary. "Having the expertise and support of the world's leading MRI manufacturer not only helps position us for success but also underscores the importance of molecular MRI to the broader diagnostic imaging market."

To date, MRI contrast agents have been general-purpose, improving image resolution by creating contrast at tissue boundaries or within tissue, but lacking molecular specificity required to make a concrete diagnosis. Imagion's MagSense® imaging agents could change this by enabling a first-of-its-kind molecular imaging solution for MRI. By changing current practice in medical imaging to include the sensitive and selective detection of cancer cells without

using radiation, Imagion's technology could significantly improve cancer diagnosis and patient care, reducing unnecessary biopsies and leading to earlier, better informed treatment decisions.

In the successfully completed Phase 1 study, also supported by Siemens Healthineers, a panel of independent radiologists ascertained that the MagSense® HER2 Imaging Agent produced a readily identifiable change in MRI images to differentiate between tumour involved nodes and non-involved nodes. The Phase 1b/2 clinical trial will establish the optimized dose of the imaging agent, the optimum imaging timing, as well as accumulate data for diagnostic performance. Entering into a Phase 1b/2 trial represents a significant milestone for Imagion, providing multiple data outputs as the MagSense technology progresses towards commercialisation.

While the collaboration with Siemens Healthineers will primarily support the successful conduct of the MagSense® HER2 Imaging Agent Phase 2 clinical trial, the collaboration is expected to continue as clinical development of Imagion's additional pipeline candidates, including indications in prostate and ovarian cancers, progress.

About the MagSense® Imaging Agent Technology

MagSense® technology is a new class of MRI imaging agents that improves cancer detection compared to conventional imaging technologies by adding molecular specificity without using radioactivity. MagSense® agents will be the first imaging technology to use targeted magnetic nanoparticles to tag and detect cancers allowing for visualisation using MRI. This new class of imaging agents does not use ionizing radiation or radioactive tracers and improves how medical imaging can be used compared to conventional imaging methods which only identify a region of interest using anatomical or morphological features but cannot differentiate benign tumours from malignant cancer. Imagion has developed MagSense® imaging agents for three different types of cancer. The lead product has completed a Phase 1 study for the detection of nodal metastases (spread) in HER2+ breast cancer and is now advancing into a Phase 1b/2 study. The MagSense® technology is also extendable, with two additional agents for prostate cancer and ovarian cancer having been identified and could progress into IND-enabling studies as resources become available.

Authorization & Additional Information

This announcement was authorized by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com.

###

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imaginationbiosystems.com.

Executive Chairman Contact Details

Bob Proulx

investor@imaginationbio.com

AU: +61 3 9692 7222

Media Enquiries & Investor Relations

Erich Boileau, Boileau & Co.

imaginationbio@boileau.co

US: +1 (616) 786-4461

For personal use only